Search alternatives:
greatest decrease » greater decrease (Expand Search), treatment decreased (Expand Search), greater increase (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 1,301 - 1,320 results of 48,899 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ( a ((greatest decrease) OR (largest decrease)) ))', query time: 0.86s Refine Results
  1. 1301
    Dexamethasone decreases PGC-1α protein expression and transcription.

    Dexamethasone decreases PGC-1α protein expression and transcription. by Jill A. Rahnert (2872766)

    Published 2016
    “…<p>(A) Treatment of L6 myotubes with Dex (100nM, 48hrs) decreased PGC-1α protein expression (p = 0.01). n = 3/treatment from 3 experiments. …”
    Save to List
    Saved in:
  2. 1302
    Effect of decreased endogenous betaglycan expression on metanephric development and glomerulogenesis.

    Effect of decreased endogenous betaglycan expression on metanephric development and glomerulogenesis. by Kenneth A. Walker (280683)

    Published 2013
    Save to List
    Saved in:
  3. 1303
    Dexamethasone decreases CRTC1 and CRTC2 nuclear localization.

    Dexamethasone decreases CRTC1 and CRTC2 nuclear localization. by Jill A. Rahnert (2872766)

    Published 2016
    “…<p>Treatment of L6 myotubes with Dex (100nM, 48hrs) decreased (A) total CRTC1 (p = 0.004 and CRTC2 protein (p = 0.0007). n = 9/treatment from 3 experiments. …”
    Save to List
    Saved in:
  4. 1304
    (Related to Fig 2A). Comparison of mean percentages of transfected cells with SGs calculated from three biological triplicates, showing the decrease in %, as compared to the control (pEGF-N3-transfected cells, “GFP”).

    (Related to Fig 2A). Comparison of mean percentages of transfected cells with SGs calculated from three biological triplicates, showing the decrease in %, as compared to the control (pEGF-N3-transfected cells, “GFP”). by Chiara Aloise (8374950)

    Published 2023
    Save to List
    Saved in:
  5. 1305
    Long-lived acceptor dark states can produce bimodal FRET efficiency distributions, multi-exponential donor excited-state decays, and a decrease in measured average FRET efficiency compared with that for the mean separation.

    Long-lived acceptor dark states can produce bimodal FRET efficiency distributions, multi-exponential donor excited-state decays, and a decrease in measured average FRET efficiency compared with that for the mean separation. by Steven S. Vogel (299330)

    Published 2013
    Save to List
    Saved in:
  6. 1306
    Percent accuracy and mean reaction time across the TLDB task.

    Percent accuracy and mean reaction time across the TLDB task. by David Apreutesei (19429483)

    Published 2024
    Save to List
    Saved in:
  7. 1307
    Mean body weight.

    Mean body weight. by Shane R. McClafferty (19434460)

    Published 2024
    Save to List
    Saved in:
  8. 1308
    Main parameters and meanings.

    Main parameters and meanings. by Tiaojuan Han (18196471)

    Published 2024
    Save to List
    Saved in:
  9. 1309
    Intrathecal delivery of IL-6 increases cAMP and AC levels and decreases PDE level in the sensorimotor cortex.

    Intrathecal delivery of IL-6 increases cAMP and AC levels and decreases PDE level in the sensorimotor cortex. by Ping Yang (56755)

    Published 2015
    “…<p>Seven days after intrathecal delivery of IL-6, IL-6 and AG-490, or saline, cAMP, AC and PDE levels in the sensorimotor cortex were determined by ELISA. cAMP (A) and AC (C) levels increased while PDE (B) level decreased in IL-6 delivery group compared with that of saline group. …”
    Save to List
    Saved in:
  10. 1310
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 1311
    The impact of a breast cancer diagnosis on health-related quality of life. A prospective comparison among middle-aged to elderly women with and without breast cancer

    The impact of a breast cancer diagnosis on health-related quality of life. A prospective comparison among middle-aged to elderly women with and without breast cancer by Randi V. Karlsen (2545756)

    Published 2016
    “…<p><b>Background</b> The improved survival after breast cancer has prompted knowledge on the effect of a breast cancer diagnosis on health-related quality of life (HQoL). …”
    Save to List
    Saved in:
  12. 1312
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 1313
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 1314
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 1315
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 1316
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 1317
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 1318
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 1319
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 1320
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: